The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1 EVX-V1 is a next-generation, multi-component vaccine program combining novel AI-discovered antigens with AI-optimized versions of established
New preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine candidate Poster presentation on July 12, 2026, at the International Herpesvirus Workshop 2026 taking place in Montreal, Canada COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ: EVAX)
COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology™.
EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activation The vaccine antigens drive specific immune responses across different human immune profiles and induce targeted cell-killing Poster presentation at the European Hematology Association (EHA) 2026
Data will reflect the functional characterization of EVX-04 Poster presentation on June 13, 2026 COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce the
COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.
COPENHAGEN, Denmark, May 4, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its first quarter 2026 financial results on Thursday May 7, 2026, before
Management remit expansion reflecting organization alignment to maximize external engagement and strategy execution COPENHAGEN, Denmark, April 27, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform,
New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response The results reinforce that Evaxion’s pioneering AI platform, AI-Immunology™ accurately identifies and selects the most relevant vaccine targets
Data analysis conducted in collaboration with a leading academic medical center shows that AI ‑ Immunology™ enables vaccine design also for the deadly brain cancer, glioblastoma Uniquely, the platform can identify a novel source of targets to include in glioblastoma cancer vaccines, potentially
COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, held its Annual General Meeting today at the company’s offices. The 2025 Annual Report was approved and the Board of
Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026 The trial has already yielded encouraging one- and two-year data including a 75% Objective Response Rate COPENHAGEN, Denmark, April 7, 2026 - Evaxion A/S (NASDAQ: EVAX)
Using its pioneering AI-platform, AI-Immunology™, Evaxion has, in collaboration with the Gates Foundation, developed novel design concepts for polio vaccines potentially superior to those currently used The AI-Immunology™ concepts include hybrid capsid designs and de novo designed B-cell antigen
COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its Annual General Meeting is convened to be held on April 16, 2026, at 14.00 CET.
Two abstracts accepted for presentation One abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01 Another abstract on the use of Evaxion’s AI-Immunology™ platform in developing a personalized cancer vaccine strategy for glioblastoma (brain cancer)
COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces full year 2025 financial results.
COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing and publication of its 2025 annual report, planned before opening of Nasdaq CM today,